[{"address1": "Wallstrasse 16", "city": "Berlin", "zip": "10179", "country": "Germany", "phone": "49 89 2153 9035", "fax": "49 89 2153 90351", "website": "https://www.atai.life", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.", "fullTimeEmployees": 83, "companyOfficers": [{"maxAge": 1, "name": "Mr. Christian  Angermayer", "age": 46, "title": "Founder & Chairman of the Supervisory Board", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 70000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Srinivas G. Rao M.D., Ph.D.", "age": 55, "title": "Co-Founder & CEO", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 793650, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Anne  Johnson", "age": 55, "title": "Chief Financial Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 494232, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gerd G. Kochendoerfer Ph.D.", "age": 56, "title": "Chief Operating Officer", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Frank  Stegert", "age": 43, "title": "Vice President of Investment & Venture Management", "yearBorn": 1981, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Glenn  Short Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Barrett J.D.", "age": 42, "title": "General Counsel & Corporate Secretary", "yearBorn": 1982, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sahil V. Kirpekar M.D.", "age": 38, "title": "Chief Business Officer", "yearBorn": 1986, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kevin  Craig M.D.", "title": "Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.65, "open": 1.63, "dayLow": 1.57, "dayHigh": 1.745, "regularMarketPreviousClose": 1.65, "regularMarketOpen": 1.63, "regularMarketDayLow": 1.57, "regularMarketDayHigh": 1.745, "payoutRatio": 0.0, "beta": 1.227, "forwardPE": -2.5294118, "volume": 1885208, "regularMarketVolume": 1885208, "averageVolume": 2718415, "averageVolume10days": 4769450, "averageDailyVolume10Day": 4769450, "bid": 1.26, "ask": 2.03, "bidSize": 2, "askSize": 2, "marketCap": 333667936, "fiftyTwoWeekLow": 1.03, "fiftyTwoWeekHigh": 2.85, "priceToSalesTrailing12Months": 1008.06024, "fiftyDayAverage": 1.6698, "twoHundredDayAverage": 1.455, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 229503120, "profitMargins": 0.0, "floatShares": 126090076, "sharesOutstanding": 193992992, "sharesShort": 11160861, "sharesShortPriorMonth": 11546149, "sharesShortPreviousMonthDate": 1736899200, "dateShortInterest": 1739491200, "sharesPercentSharesOut": 0.0575, "heldPercentInsiders": 0.10018, "heldPercentInstitutions": 0.34519002, "shortRatio": 3.07, "shortPercentOfFloat": 0.0723, "impliedSharesOutstanding": 193992992, "bookValue": 0.868, "priceToBook": 1.9815669, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -128603000, "trailingEps": -0.8, "forwardEps": -0.68, "enterpriseToRevenue": 693.363, "enterpriseToEbitda": -2.214, "52WeekChange": -0.21052629, "SandP52WeekChange": 0.14239466, "quoteType": "EQUITY", "currentPrice": 1.72, "targetHighPrice": 11.0, "targetLowPrice": 5.0, "targetMeanPrice": 8.0, "targetMedianPrice": 8.0, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 4, "totalCash": 85920000, "totalCashPerShare": 0.512, "ebitda": -103638000, "totalDebt": 26207000, "quickRatio": 4.438, "currentRatio": 5.807, "totalRevenue": 331000, "debtToEquity": 17.911, "revenuePerShare": 0.002, "returnOnAssets": -0.25702, "returnOnEquity": -0.62773, "grossProfits": 331000, "freeCashflow": -65382248, "operatingCashflow": -80104000, "revenueGrowth": -0.54, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -565.05, "financialCurrency": "USD", "symbol": "ATAI", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1740790072, "regularMarketTime": 1740776401, "exchange": "NGM", "messageBoardId": "finmb_710359021", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 4.242428, "regularMarketPrice": 1.72, "shortName": "ATAI Life Sciences N.V.", "longName": "Atai Life Sciences N.V.", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 2718415, "fiftyTwoWeekLowChange": 0.69000006, "fiftyTwoWeekLowChangePercent": 0.669903, "fiftyTwoWeekRange": "1.03 - 2.85", "fiftyTwoWeekHighChange": -1.1299999, "fiftyTwoWeekHighChangePercent": -0.3964912, "fiftyTwoWeekChangePercent": -21.05263, "earningsTimestampStart": 1742992200, "earningsTimestampEnd": 1743424200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.8, "epsForward": -0.68, "epsCurrentYear": -0.75667, "priceEpsCurrentYear": -2.2731178, "fiftyDayAverageChange": 0.050199986, "fiftyDayAverageChangePercent": 0.03006347, "twoHundredDayAverageChange": 0.265, "twoHundredDayAverageChangePercent": 0.18213058, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-06-18", "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1624023000000, "postMarketChangePercent": 0.0, "postMarketPrice": 1.72, "postMarketChange": 0.0, "regularMarketChange": 0.07000005, "regularMarketDayRange": "1.57 - 1.745", "marketState": "CLOSED", "displayName": "Atai Life Sciences", "trailingPegRatio": null, "__fetch_time": "2025-03-01"}]